QUANTERIX CORP. DL-,001

Quanterix reported Q2 revenue of $32.9 million and revised full‑year 2026 revenue guidance down to $142–148 million from $169–174 million, citing market softness and executional shortfalls. Management is reorganizing its commercial organization, hiring industry veterans including Jim Gute and expanding its diagnostics focus around LucentAD, while completing the Akoya integration and realizing $85 million of annualized synergies. The company ended Q2 with $96.9 million in cash, now expects roughly $80 million at year‑end and pushed cash‑flow break‑even into 2027; non‑GAAP gross margin guidance is narrowed to 48–50%. » More on finance.yahoo.com

Quanterix has fully integrated the Akoya acquisition and, according to management, realized revenue synergies of $85 million. The company is reorganizing sales by product line to serve Spatial, Simoa and clinical studies separately, and is refilling key roles in commercial and diagnostics. The focus is the blood test LucentAD Complete (510(k) application with the FDA, approval expected end-2024/early-2025) and expanding the commercialization infrastructure; in the short term Q3 revenue is expected to be flat with a sequential improvement in Q4. Achieving cash-flow break-even is postponed to 2025. Diagnostics revenue for 2024 is forecast at about $10 million, with the aim of meeting or exceeding the diagnostics revenue target for 2026. » More on de.investing.com

Quanterix reported Q2 revenue of $32.9 million, well below the consensus expectation of $38.06 million. The company lowered its full-year guidance to $142–148 million, pushed expected cash-flow breakeven to 2027, and announced a reorganization of its sales team. The stock fell about 42.9% in after-hours trading to $2.30, while Quanterix held $96.9 million in cash and is increasingly focusing on diagnostic products such as LucentAD Complete. » More on de.investing.com